Catalona William J
Department of Urology, Northwestern University Feinberg School of Medicine, 675 North Saint Clair Street, Suite 20-150, Chicago, IL 63110, USA.
Med Clin North Am. 2018 Mar;102(2):199-214. doi: 10.1016/j.mcna.2017.11.001.
During the prostate-specific antigen-based prostate cancer (PCa) screening era there has been a 53% decrease in the US PCa mortality rate. Concerns about overdiagnosis and overtreatment combined with misinterpretation of clinical trial data led to a recommendation against PCa screening, resulting in a subsequent reversion to more high-risk disease at diagnosis. Re-evaluation of trial data and increasing acceptance of active surveillance led to a new draft recommendation for shared decision making for men aged 55 to 69 years old. Further consideration is needed for more intensive screening in men with high-risk factors. PCa screening significantly reduces PCa morbidity and mortality.
在基于前列腺特异性抗原的前列腺癌（PCa）筛查时代，美国PCa死亡率下降了53%。对过度诊断和过度治疗的担忧，再加上对临床试验数据的错误解读，导致了反对PCa筛查的建议，结果在诊断时又恢复到更多的高危疾病。对试验数据的重新评估以及对主动监测越来越多的认可导致了一项针对55至69岁男性共同决策的新建议草案。对于有高危因素的男性进行更密集的筛查还需要进一步考虑。PCa筛查显著降低了PCa发病率和死亡率。
